📊 IVF Key Takeaways
Is IVF a Good Investment? Thesis Analysis
INVO Fertility is in severe financial distress with negative profitability across all margins, critical liquidity crisis (current ratio of 0.12x), and substantial cash burn exceeding $7M annually. The company is losing $481.80 for every dollar of revenue generated, indicating fundamental business model challenges that cannot be attributed to early-stage development.
Why Buy IVF? Key Strengths
- Debt/Equity ratio of 0.34x indicates relatively moderate leverage
- Minimal capital expenditure suggests controlled cash outflow in non-operating areas
- Presence in surgical medical instruments sector provides potential market opportunity
IVF Investment Risks to Consider
- Critical liquidity crisis with current ratio of 0.12x and only $355.9K cash against $13.0M liabilities
- Catastrophic profitability: -481.8% net margin and -110.8% operating margin indicating unsustainable business model
- Severe cash burn with operating cash flow of -$7.0M and free cash flow of -$7.1M threatening near-term solvency
- Revenue of only $5.3M with negative growth (-0.4% YoY) and minimal gross margin of 5.2%
- Net loss of $25.3M substantially exceeds annual revenue by 477%, indicating massive operating losses
Key Metrics to Watch
- Cash position and burn rate trajectory to assess solvency timeline
- Operating cash flow and path to positive FCF generation
- Revenue growth and gross margin expansion to validate business model viability
- Liquidity ratios and ability to meet near-term obligations
IVF Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IVF Profitability Ratios
IVF vs Healthcare Sector
How INVO Fertility, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IVF Overvalued or Undervalued?
Based on fundamental analysis, INVO Fertility, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IVF Balance Sheet & Liquidity
IVF 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: INVO Fertility, Inc.'s revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $-67.37 indicates the company is currently unprofitable.
IVF Growth Metrics (YoY)
IVF Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $1.6M | -$1.6M | $-7.55 |
| Q3 2024 | $974.9K | -$1.2M | $-0.42 |
| Q2 2024 | $315.9K | -$1.6M | $-0.62 |
| Q1 2024 | $348.0K | -$1.6M | $-0.42 |
| Q3 2023 | $235.3K | -$1.2M | $-0.70 |
| Q2 2023 | $146.1K | -$2.2M | $-3.06 |
| Q1 2023 | $162.6K | -$2.6M | $-0.20 |
| Q3 2022 | $218.9K | -$2.2M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IVF Capital Allocation
IVF SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for INVO Fertility, Inc. (CIK: 0001417926)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVF
What is the AI rating for IVF?
INVO Fertility, Inc. (IVF) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVF's key strengths?
Claude: Debt/Equity ratio of 0.34x indicates relatively moderate leverage. Minimal capital expenditure suggests controlled cash outflow in non-operating areas.
What are the risks of investing in IVF?
Claude: Critical liquidity crisis with current ratio of 0.12x and only $355.9K cash against $13.0M liabilities. Catastrophic profitability: -481.8% net margin and -110.8% operating margin indicating unsustainable business model.
What is IVF's revenue and growth?
INVO Fertility, Inc. reported revenue of $5.3M.
Does IVF pay dividends?
INVO Fertility, Inc. does not currently pay dividends.
Where can I find IVF SEC filings?
Official SEC filings for INVO Fertility, Inc. (CIK: 0001417926) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVF's EPS?
INVO Fertility, Inc. has a diluted EPS of $-17.83.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IVF a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, INVO Fertility, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IVF stock overvalued or undervalued?
Valuation metrics for IVF: ROE of -433.1% (sector avg: 15%), net margin of -481.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IVF stock in 2026?
Our dual AI analysis gives INVO Fertility, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVF's free cash flow?
INVO Fertility, Inc.'s operating cash flow is $-7.0M, with capital expenditures of $31.6K. FCF margin is -134.5%.
How does IVF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -481.8% (avg: 12%), ROE -433.1% (avg: 15%), current ratio 0.12 (avg: 2).